Felicity Thomas
European Editor at Pharmaceutical Technology
Host at Drug Solutions
Editor, journalist, dabbler in IT sales support and baking, netball player and rugby union enthusiast. Mainly a mum.
Articles
-
1 week ago |
biopharminternational.com | Felicity Thomas |Susan Haigney
The post-COVID-19 era has seen the consequences of ambitious programs launched during the pandemic, according to Erik Wiklund, CEO of Circio, such as a lack of capital for small biotech and employee layoffs, and Wiklund sees this impacting the industry during 2025. “Many companies launch great ambitions, large valuations.
-
1 week ago |
biopharminternational.com | Felicity Thomas |Susan Haigney
Edwin Stone, CEO of Cellular Origins, sees two themes having the biggest impact to the bio/pharma industry: the expansion of glucagon-like peptide-1 (GLP-1) and the growth of cell therapies from fourth- and third-line treatments to second-line treatments. “It really opens up that question of, when do we start to see first line treatments? And of course, part of that comes down to not just the safety and efficacy profiles, but the cost of goods, which still no one has a good answer to,” Stone says.
-
1 month ago |
biopharminternational.com | Felicity Thomas |Susan Haigney
In this episode of Ask the Expert, Dirk Margosch, Vice President Visual Inspection, Assembly & Secondary Packaging at Vetter Pharma-Fertigung GmbH & Co KG, addresses the benefits of automating visual inspection, which include increased efficiency and accuracy, and what goes into the cost versus benefit of automating inspection of small batches. “[T] he decision to continue manual inspection for small batch sizes involves several considerations,” says Margosch.
-
1 month ago |
biopharminternational.com | Felicity Thomas
Therapeutic modalities are diversifying across the bio/pharma industry, explains Simon Wright, vice president of Business Development for Almac Pharma Services. “Whilst there remains a strong demand for traditional small molecules, we see a higher percentage growth in areas such as biologics, vaccines, cell and gene therapies, and I guess, most recently, peptides,” he says.
-
1 month ago |
biopharminternational.com | Felicity Thomas
While the pharmaceutical industry has made strides towards diversity, equity, and inclusion, there is still room for improvement, asserts Sheryl Johnson, pharma application development manager at Orbia Fluor & Energy Materials. Many companies, such as Orbia, are taking proactive approaches to help improve gender diverse representations within their workforces. Ongoing commitment from all areas across the industry is required to achieve full diversity, she explains.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 126
- Tweets
- 124
- DMs Open
- No
Could traffic cone be Aled Jones #MaskedSingerUK
Lion fish has to be Will Young #MaskedSingerUK
Could Mushroom be Duffy? @MaskedSingerUK
